Astrazeneca (AZN) Other Accumulated Expenses (2009 - 2026)

Astrazeneca's Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at -$2.2 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 5.74% year-over-year to -$2.2 billion; the TTM figure through Mar 2026 stood at -$2.2 billion (down 5.74% YoY), while the FY2025 annual figure was -$2.4 billion, down 34.41% from the prior year.
• Other Accumulated Expenses was -$2.2 billion for Q1 2026 at Astrazeneca, up from -$2.4 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of -$1.6 billion in Q2 2025 to a low of -$4.9 billion in Q3 2022.
• Historically, Other Accumulated Expenses has averaged -$2.7 billion across 5 years, with a median of -$2.4 billion in 2025.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses soared 54.04% in 2023, then tumbled 34.41% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at -$4.3 billion in 2022, then surged by 37.7% to -$2.7 billion in 2023, then jumped by 33.46% to -$1.8 billion in 2024, then sank by 34.41% to -$2.4 billion in 2025, then increased by 9.42% to -$2.2 billion in 2026.
• The last three Other Accumulated Expenses figures came in at -$2.2 billion (Q1 2026), -$2.4 billion (Q4 2025), and -$2.0 billion (Q3 2025), per Business Quant data.